Literature DB >> 33590347

Dehydroabietic acid improves nonalcoholic fatty liver disease through activating the Keap1/Nrf2-ARE signaling pathway to reduce ferroptosis.

Gai Gao1,2, Zhishen Xie1, Er-Wen Li1, Yong Yuan1, Yu Fu2, Pan Wang1, Xiaowei Zhang1, Yonghui Qiao1, Jiangyan Xu1, Christian Hölscher1, Hui Wang3, Zhenqiang Zhang4.   

Abstract

The accumulation of iron-dependent lipid peroxides is one of the important causes of NAFLD. The purpose of this study is to explore the effect of dehydroabietic acid (DA) on ferroptosis in nonalcoholic fatty liver disease (NAFLD) mice and its possible mechanisms. DA improved NAFLD and reduced triglycerides (TG), total cholesterol (TC), and lipid peroxidation level and inhibited ferroptosis in the liver of HFD-induced mice. DA binds with Keap1 to form 3 stable hydrogen bonds at VAL512 and LEU557 and increased nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant response elemen (ARE) luciferase activity. DA promoted the expression downstream of Nrf2 such as heme oxygenase-1 (HO-1), glutathione (GSH) and its peroxidase 4 (GPX4), so as to eliminate the accumulation of reactive oxygen species (ROS) and reduce lipid peroxides malondialdehyde (MDA) in the liver. DA inhibited ferroptosis and increased the expression of key genes such as ferroptosis suppressor protein 1 (FSP1) in vitro and vivo. In all, DA may bind with Keap1, activate Nrf2-ARE, induce its target gene expression, inhibit ROS accumulation and lipid peroxidation, and reduce HFD-induced NAFLD.

Entities:  

Keywords:  Dehydroabietic acid; Ferroptosis; Nonalcoholic fatty liver disease; Nrf2-ARE; ROS

Year:  2021        PMID: 33590347     DOI: 10.1007/s11418-021-01491-4

Source DB:  PubMed          Journal:  J Nat Med        ISSN: 1340-3443            Impact factor:   2.343


  65 in total

Review 1.  Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.

Authors:  Leon A Adams; Quentin M Anstee; Herbert Tilg; Giovanni Targher
Journal:  Gut       Date:  2017-03-17       Impact factor: 23.059

Review 2.  Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis.

Authors:  Alessandro Mantovani; Gianluigi Zaza; Christopher D Byrne; Amedeo Lonardo; Giacomo Zoppini; Enzo Bonora; Giovanni Targher
Journal:  Metabolism       Date:  2017-11-11       Impact factor: 8.694

3.  The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study.

Authors:  Alina M Allen; Stephen B Hicks; Kristin C Mara; Joseph J Larson; Terry M Therneau
Journal:  J Hepatol       Date:  2019-08-27       Impact factor: 25.083

Review 4.  Evolution of NAFLD and Its Management.

Authors:  Manpreet S Mundi; Saketh Velapati; Janki Patel; Todd A Kellogg; Barham K Abu Dayyeh; Ryan T Hurt
Journal:  Nutr Clin Pract       Date:  2019-12-16       Impact factor: 3.080

Review 5.  Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.

Authors:  Anna M Diehl; Christopher Day
Journal:  N Engl J Med       Date:  2017-11-23       Impact factor: 91.245

6.  Publisher Correction: The gut-liver axis and the intersection with the microbiome.

Authors:  Anupriya Tripathi; Justine Debelius; David A Brenner; Michael Karin; Rohit Loomba; Bernd Schnabl; Rob Knight
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-12       Impact factor: 46.802

Review 7.  [Nutritional Management of Nonalcoholic fatty liver disease (NAFLD)].

Authors:  Amel Ait Boudaoud; Claire Rives-Lange; Jean François Perregaux; Alina Radu; Diane Messager-Josipowicz; Charles Barsamian; Claire Carette; Sébastien Czernichow
Journal:  Presse Med       Date:  2019-11-19       Impact factor: 1.228

Review 8.  The gut-liver axis and the intersection with the microbiome.

Authors:  Anupriya Tripathi; Justine Debelius; David A Brenner; Michael Karin; Rohit Loomba; Bernd Schnabl; Rob Knight
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-07       Impact factor: 46.802

9.  Nonalcoholic fatty liver disease is associated with low HDL cholesterol and coronary angioplasty in patients with type 2 diabetes.

Authors:  Aleksandra Trojak; Małgorzata Waluś-Miarka; Ewa Woźniakiewicz; Maciej T Małecki; Barbara Idzior-Waluś
Journal:  Med Sci Monit       Date:  2013-12-16

10.  A Close Relationship between Non-Alcoholic Fatty Liver Disease Marker and New-Onset Hypertension in Healthy Korean Adults.

Authors:  Jae Hyung Roh; Jae Hyeong Park; Hanbyul Lee; Yong Hoon Yoon; Minsu Kim; Yong Giun Kim; Gyung Min Park; Jae Hwan Lee; In Whan Seong
Journal:  Korean Circ J       Date:  2020-03-23       Impact factor: 3.243

View more
  9 in total

Review 1.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

2.  Apatinib Induces Ferroptosis of Glioma Cells through Modulation of the VEGFR2/Nrf2 Pathway.

Authors:  Liang Xia; Mingjie Gong; Yangfan Zou; Zeng Wang; Bin Wu; Shuyuan Zhang; Liwen Li; Kai Jin; Caixing Sun
Journal:  Oxid Med Cell Longev       Date:  2022-05-11       Impact factor: 7.310

Review 3.  The Regulatory Roles of Polysaccharides and Ferroptosis-Related Phytochemicals in Liver Diseases.

Authors:  Yijing Ren; Siyue Li; Zixuan Song; Qiuping Luo; Yingying Zhang; Hao Wang
Journal:  Nutrients       Date:  2022-05-30       Impact factor: 6.706

Review 4.  Ferroptosis and Its Potential Role in Metabolic Diseases: A Curse or Revitalization?

Authors:  Jia-Yue Duan; Xiao Lin; Feng Xu; Su-Kang Shan; Bei Guo; Fu-Xing-Zi Li; Yi Wang; Ming-Hui Zheng; Qiu-Shuang Xu; Li-Min Lei; Wen-Lu Ou-Yang; Yun-Yun Wu; Ke-Xin Tang; Ling-Qing Yuan
Journal:  Front Cell Dev Biol       Date:  2021-07-09

Review 5.  The Emerging Role of Ferroptosis in Liver Diseases.

Authors:  Si Chen; Jun-Yao Zhu; Xin Zang; Yong-Zhen Zhai
Journal:  Front Cell Dev Biol       Date:  2021-12-14

6.  Nrf2-Mediated Ferroptosis Inhibition Exerts a Protective Effect on Acute-on-Chronic Liver Failure.

Authors:  Jing Wu; Ran Xue; Muchen Wu; Xuehong Yin; Bangxiang Xie; Qinghua Meng
Journal:  Oxid Med Cell Longev       Date:  2022-04-16       Impact factor: 7.310

7.  Protective Effect of Danshen Zexie Decoction Against Non-Alcoholic Fatty Liver Disease Through Inhibition of ROS/NLRP3/IL-1β Pathway by Nrf2 Signaling Activation.

Authors:  Yaning Biao; Jian Chen; Chenxu Liu; Ruilong Wang; Xue Han; Li Li; Yixin Zhang
Journal:  Front Pharmacol       Date:  2022-06-21       Impact factor: 5.988

Review 8.  Recent Advances on Biological Activities and Structural Modifications of Dehydroabietic Acid.

Authors:  Meng Hao; Jianwei Xu; Houpeng Wen; Jiawei Du; Shaoyong Zhang; Min Lv; Hui Xu
Journal:  Toxins (Basel)       Date:  2022-09-12       Impact factor: 5.075

Review 9.  Iron Overload, Oxidative Stress, and Ferroptosis in the Failing Heart and Liver.

Authors:  Daniele Mancardi; Mariarosa Mezzanotte; Elisa Arrigo; Alice Barinotti; Antonella Roetto
Journal:  Antioxidants (Basel)       Date:  2021-11-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.